The story behind targeting FLT3 in AML and the next generation of inhibitors
Advancements at ASH 2017 that are directly relevant to patients
How can MRD and disease be assessed in routine practice?
Small molecule inhibitors for CLL: which to use, sequencing, switching and combinations
Follow-up CAR T-cell data so far